LDS/Medical Tests/Clobazam, Serum

Clobazam, Serum

Clobazam belongs to the class of drugs known as Benzodiazepines. The benzodiazepines are a class of medications (drugs) that produce the following effects: sedation and anxiety relief. They are one of the most widely prescribed drugs in the world. Benzodiazepines have essentially replaced the use of barbiturates as the major class of CNS depressants.

Clobazam is an intermediate-acting benzodiazepine used for the treatment of epileptic seizures in children from 2 years to adult, and for treating anxiety. Clobazam is characterized as a 1,5 benzodiazepam. Clobazam is a white crystalline powder. Clobazam is slightly soluble in water and ethanol, and soluble in methylene chloride.

Clobazam is metabolized to N-desmethylclobazam by the cytochrome P450 (specifically CYP3A4A) system in hepatic tissue. Clobazam is one of the benzodiazepine classes that are typically used by drug abusers. Long-term abuse can lead to respiratory depression or, in severe cases, coma. Benzodiazepines are frequently abused drugs and associated especially with heroin and cocaine abusers. Benzodiazepines are only legally available through prescription. Many abusers obtain their supply of these drugs by acquiring several prescriptions from several different physicians, or by forging prescriptions, or by obtaining them illicitly. Alprazolam and diazepam are the two most frequently encountered benzodiazepines on the illicit market today.

Benzodiazepines generally are rapidly metabolized and excreted into the urine, allowing detection by various analytical methods such as Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay (IA) screening, and screening spot testing. Benzodiazepines can elicit the following side effects: amnesia, hostility, irritability, skin rash, allergic reactions and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, incoordination, slow speech, impaired thinking, weak and rapid pulse, coma, and possible death. Clobazam (Onfi) has been shown to cause rare, but severe, skin reactions called Stevens-Johnson syndrome and toxic epidermal necrolysis.

  • Therapeutic monitoring in blood
  • Drug abuse evaluation
  • Toxicity assessment in blood
  • Patient Compliance
A qualitative positive result from an immunoassay (IA) type test indicates only the presence of any benzodiazepine such as clobazam and is not specific and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result must be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic concentration:

Clobazam:  30-300 ng/mL

Desmethylclobazam:  300-3000 ng/mL

Toxic concentration: >5000 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

 

Cut-Off Ranges

Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as immunoassay, or a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

 

 

Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Immunoassay (IA). The main method of quantification is via LC/MS. This particular method of analysis is used to not only detect the parent drug compound, clobazam, but also the major metabolites of clobazam, such as desmethylclobazam. These active metabolites should be quantified to assess the overall concentration of clobazam. Clobazam and N-desmethylclobazam, as well as all benzodiazepines, can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis since some benzodiazepines are unstable in acid medium and rearrange to form benzophenones.

Serum (SST). 

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP2C19, CYP2B6 may be tested for drug safety and efficacy before ordered. Supportive testing such as Liver profile, Kidney profile, Thyroid function, and Comprehensive Metabolic Panel, CBC (if overdose); other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 ( Pt 5):460-510. [PMID: 9293303]
  • Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Principles of Forensic Toxicology, Fourth Edition. Ed, Barry Levine. AACC Press, Washington DC. Chapter 14, Benzodiazepines, pp. 237-251 (2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC, ed. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Foster City, CA: Biomedical Publications (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4): 7-20.
  • Rupp W, Badian M, Christ O, Hajdu P, Kulkarmi RD, Taeber K, Uihlein M, Bender R, and Vanderbeke O. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacal. 1979; 7 Suppl 1:515-575.
  • Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SSM. Clobazam as an adjuvant treatment in refractory epilepsy. Br Med J. 1983; 286, 1246-1247.